Mana yang lebih menguntungkan Rivaroxaban atau Warfarin pada Nonvalvular Atrial Fibrillation

Non valvular atrial fibrilasis merupakan salah satu faktor risiko stroke iskemia dan embolisme pada pembuluh darah. Selama ini warfarin merupakan salah satu obat pilihan untuk pencegahan strok iskemia maupun pembentukan emboli pada pasien dengan fibrilasis termasuk pasien dengan nonvalvular atrial fibrilasis. Hasil Uji klinis untuk membandingkan kemanjuran rivaroxaban dengan warfarin pada nonvalvular atrial fibrilasis telah dilaporkan oleh NEJM.

rivaroxaban

rivaroxaban

faktor risiko cvd

faktior risiko cvd

Original Article

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Günter Breithardt, M.D., Jonathan L. Halperin, M.D., Graeme J. Hankey, M.D., Jonathan P. Piccini, M.D., Richard C. Becker, M.D., Christopher C. Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the ROCKET AF Steering Committee for the ROCKET AF Investigators

N Engl J Med 2011; 365:883-891September 8, 2011

Comments open through September 14, 2011

Abstract
Article
References
Citing Articles (1)
Comments (3)

Background

The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.

Full Text of Background…

Methods

In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism.

Full Text of Methods…

Results

In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority). In the intention-to-treat analysis, the primary end point occurred in 269 patients in the rivaroxaban group (2.1% per year) and in 306 patients in the warfarin group (2.4% per year) (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for noninferiority; P=0.12 for superiority). Major and nonmajor clinically relevant bleeding occurred in 1475 patients in the rivaroxaban group (14.9% per year) and in 1449 in the warfarin group (14.5% per year) (hazard ratio, 1.03; 95% CI, 0.96 to 1.11; P=0.44), with significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, P=0.02) and fatal bleeding (0.2% vs. 0.5%, P=0.003) in the rivaroxaban group.

Full Text of Results…

Conclusions

In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.)

This entry was posted in Artikel, Info Penyakit on by .

About Webmaster

"My characteristics are:A foundation, order, service, struggle against limits, steady growth. My destiny is to express wonderful organization skills with my ever practical, down-to-earth approach. I’m the kind of person who is always willing to work those long, hard hours to push a project through to completion. My abilities to write and teach may lean toward the more technical and detailed. The positive attitudes; I am one who no doubt, fulfills obligations, and is highly systematic and orderly. I am serious and sincere, honest and faithful. It is my role to help and I am required to do a good job at everything undertake. I may express some of the negative attitudes. The obligations that my face may tend to create frustration and feelings of limitation or restriction. I may sometimes find myself nursing negative attitudes in this regard and these can keep me in a rather low mood. Avoid becoming too rigid, stubborn, dogmatic, and fixed in my opinions. I may have a tendency to develop and hold very strong likes and dislikes, and some of these may border on the classification of prejudice. The negative often produces dominant and bossy individuals who use disciplinarian to an excess. These tendencies must be avoided, hufz..I wish . Finally, I must keep my eye on the big picture and not get overly wrapped up in detail and routine. My desire in life is personal expression, and generally enjoying life to its fullest. I want to participate in an active social life and enjoy a large circle of friends. I want to be in the limelight, expressing my artistic or intellectual talents. Word skills may be my thing; speaking, writing, acting. In a positive sense is friendly, outgoing and always very social. I have a decidedly upbeat attitude that is rarely discouraged; a good mental and emotional balance. My Soul Urge gives intuitive insight, thus, very high creative and inspirational tendencies. The truly outstanding trait shown is that of self-expression, regardless of the field of endeavor. On the negative side, I may at times become too easygoing and too optimistic, tending to scatter forces and accomplish very little. Often, the excessive 3 energy produces non-stop talkers. Everyone has faults, but my urge doesn't appreciate having these pointed out. I dream of being a leader and one who is in charge. I want to be known for my courage, daring, and original ideas. I seek unconquered heights. People may get a first impression that I am very aggressive and sure of myself.

Leave a Reply

Your email address will not be published. Required fields are marked *